Canis ISSN: 2398-2942

Levetiracetam

Synonym(s): Keppra

Contributor(s): Simon Platt

Introduction

Name

  • IUPAC.

Class of drug

  • Anticonvulsant.

Description

Chemical name

  • 2-(2-oxopyrrolidin-1-yl)butanamide.

Molecular formula

  • C8H14N2O2

Molecular weight

  • 170.209

Physical properties

  • Levetiracetam is a white to off-white crystalline powder with a faint odor and a bitter taste.

Storage requirements

  • Store in tightly closed container at room temperature away from heat and direct sunlight.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Adjunct therapy for canine seizures refractory to standard medication.
  • Levetiracetam has been documented as the most well tolerated anti-epileptic drug in humans, with adverse reactions equivalent to placebo. Overall, this drug is proven to be a highly effective adjunctive therapy in humans to control seizures refractory to treatment.
  • It will be a useful drug to consider in dogs suffering from hepatic dysfunction or from phenobarbital liver insufficiency, allowing reduction of the phenobarbital dosage.
  • Recent reports demonstrate that levetiracetam is effective in reducing seizure frequency initially in over 50% of dogs but most dogs experience an increase in their seizure frequency after 4-8 months of treatment.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmacokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMedResource.
  • Volk H A, Matiasek L A, Luján Feliu-Pascual A et al (2007) The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. Vet J 176 (3), 310-319 PubMed.
  • Chandler K (2006) Canine epilepsy: what can we learn from human seizure disorders? Vet J 172 (2), 207-217 PubMed.
  • Benedetti M S, Coupez R, Whomsley R et al (2004) Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog. Xenobiotica 34 (3), 281-300 PubMed.
  • Isoherranen N, Yagen B, Soback S et al (2001) Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs. Epilepsia 42 (7), 825-830 PubMed.
  • Genton P, Van Vleymen B (2000) Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord (2), 99-105 PubMed.
  • Isoherranen N, Roeder M, Soback S et al (2000) Enantioselective analysis of levetiracetam and its enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection. J Chromatogr B Biomed Sci Appl 745 (2), 325-332 PubMed.

Other sources of information

  • Dewey C W, Bailey K S, Badgely B L & Boothe D M (2007) Pharmokinetics of a single-dose intravenous levetiracetam administration in normal dogs. J Vet Int Med 21 (3), 592.
  • Patterson E E, Leppik I E, O'Brien T D, Goel V, Fisher J E, Dunn A W, Cloyd J C (2007) Safety and pharmokinetics of intramuscular and intravenous levetiracetam in dogs. J Vet Int Med 21 (3), 592.

ADDED